Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib Maintenance After BEAM Allo-Transplant in Relapsed High-Risk MM
NCT02504359Phase 1Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jul 2015
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixazomib in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Transplant Related Mortality at Day 100 and Incidence of Grade III-IV Acute GvHD and Ixazomib Related Toxicity at 2 years. Started Jul 2015; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT02504359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504359.